Identification of novel markers to predict response to anti-PD-1 immunotherapy in melanoma applying proteomics

• serum glycoproteomics, serum depletion to enrich low abundant proteins using baseline serum samples  (biobank USZ Prof. Levesque) of responder and non-responder to anti-PD-1 immunotherapy

• application of high sensitive mass spectrometry (i.e. timsTOF) and different bioinformatic tools

• quantification by selected reaction monitoring

• functional assays and exosomal enrichment

• clinical validation

Identification of drug resistance mechanisms to targeted and immune therapy by proteome characterisation of drug sensitive and resistant melanoma tumor cells or tissue

• identification of a resistance signature

• functional and clinical validation of the signature

Comprehensive analysis of proteomics, metabolomics and lipidomics in blood plasma of patients treated with Extracorporeal Photopheresis (ECP)

• shotgun proteomics, metabolomics and lipidomics of serum samples before and after photopheresis for the evaluation of the acting mechanism

• functional assays with different immune cells

Project in planning: Metabolomics and MS fingerprints of melanoma patients receiving immune therapy and of patients with different inflammatory background